Enzyme replacement therapy on hypophosphatasia mouse model
- 27 August 2013
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (2), 309-317
- https://doi.org/10.1007/s10545-013-9646-7
Abstract
Hypophosphatasia (HPP) is an inborn error of metabolism caused by deficiency of the tissue-nonspecific alkaline phosphatase (TNSALP), resulting in a defect of bone mineralization. Natural substrates for this ectoenzyme accumulate extracellulary including inorganic pyrophosphate (PPi), an inhibitor of mineralization, and pyridoxal 5-phosphate (PLP), a co-factor form of vitamin B6. Enzyme replacement therapy (ERT) for HPP by functional TNSALP is one of the therapeutic options. The C-terminal-anchorless human recombinant TNSALP derived from Chinese hamster ovary cell lines was purified. TNSALP-null mice (Akp2-/-), an infantile model of HPP, were treated from birth using TNSALP and vitamin B6 diet. Long-term efficacy studies of ERT consisted of every 3 days subcutaneous or intravenous injections till 28 days old (dose 20 U/g) and subsequently every 3 days intravenous injections for 6 months (dose 10 U/g). We assessed therapeutic effect by growth and survival rates, fertility, skeletal manifestations, and radiographic and pathological finding. Treated Akp2-/- mice grew normally till 4 weeks and appeared well with a minimum skeletal abnormality as well as absence of epilepsy, compared with untreated mice which died by 3 weeks old. The prognosis of TNSALP-treated Akp2-/- mice was improved substantially: 1) prolonged life span over 6 months, 2) improvement of the growth, and 3) normal fertility. After 6 months of treatment, we found moderate hypomineralization with abnormal proliferative chondrocytes in growth plate and articular cartilage. In conclusion, ERT with human native TNSALP improves substantial clinical manifestations in Akp2-/- mice, suggesting that ERT with anchorless TNSALP is also a potential therapy for HPP.This publication has 19 references indexed in Scilit:
- Enzyme-Replacement Therapy in Life-Threatening HypophosphatasiaThe New England Journal of Medicine, 2012
- Dose response of bone-targeted enzyme replacement for murine hypophosphatasiaBone, 2011
- Enzyme Replacement Therapy Prevents Dental Defects in a Model of HypophosphatasiaJournal of Dental Research, 2011
- Enzyme Replacement Therapy for Murine HypophosphatasiaJournal of Bone and Mineral Research, 2008
- Novel Mouse Model of Autosomal Semidominant Adult Hypophosphatasia Has a Splice Site Mutation in the Tissue Nonspecific Alkaline Phosphatase Gene Akp2Journal of Bone and Mineral Research, 2007
- Enhancement of drug delivery to bone: Characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptideMolecular Genetics and Metabolism, 2006
- Production of MPS VII mouse (Gustm(hE540Amiddle dotmE536A)Sly) doubly tolerant to human and mouse beta-glucuronidaseHuman Molecular Genetics, 2003
- Mice lacking tissue non–specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B–6Nature Genetics, 1995
- Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5'-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase.JCI Insight, 1988
- Infantile hypophosphatasia: Enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone diseaseThe Journal of Pediatrics, 1982